Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
Balchem (NASDAQ: BCPC) reported fourth-quarter and full-year 2025 results on Feb 20, 2026, with record full-year net sales of $1.037 billion and record adjusted EBITDA of $274.9 million. Fourth-quarter net sales were $263.6 million and GAAP net earnings were $39.2 million.
The company reported record 2025 free cash flow of $173.6 million, diluted GAAP EPS of $4.75 for the year, and said it raised its dividend by a double-digit percentage.
Positive
- Full-year net sales of $1.037 billion, record
- GAAP net earnings rose 20.5% to $154.8 million
- Adjusted EBITDA record of $274.9 million, up 9.8%
- Free cash flow record of $173.6 million for 2025
- Q4 cash from operations of $67.3 million and strong free cash flow
Negative
- None.
News Market Reaction – BCPC
In the Feb 20 session, BCPC declined 2.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 21 | Earnings results | Positive | +4.1% | Q3 2025 results with higher sales, earnings, and adjusted EBITDA. |
| Jul 31 | Earnings results | Positive | +0.3% | Q2 2025 record net sales, earnings, and adjusted EBITDA across segments. |
| Apr 24 | Earnings results | Positive | -2.6% | Q1 2025 record sales and strong profit growth in all segments. |
| Feb 21 | Earnings results | Positive | +1.5% | Q4 and full-year 2024 record sales, earnings, and strong cash flows. |
| Oct 25 | Earnings results | Positive | +3.2% | Q3 2024 net sales growth, record operations earnings, and higher EBITDA. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have generally led to positive price reactions, with four of the last five earnings events posting gains despite occasional negative moves on strong results.
Across the last year, Balchem repeatedly reported record quarterly and annual results, with rising net sales, net earnings, and adjusted EBITDA highlighted in Q1–Q3 2025 and Q4/FY 2024. All three segments consistently contributed to growth, and leverage metrics remained low. Earnings headlines often emphasized record sales and expanding cash generation, and prior earnings days typically saw modest positive share reactions, framing today’s strong Q4 and full-year 2025 report within a steady growth trajectory.
Key Terms
adjusted EBITDA financial
free cash flow financial
gross margin financial
operating expenses financial
earnings from operations financial
non-GAAP financial measures financial
net debt financial
leverage ratio financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MONTVALE, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today financial results for its 2025 fiscal fourth quarter and full year ended December 31, 2025. For the quarter, the Company reported net sales of
Ted Harris, Chairman, President, and CEO of Balchem said, “In the fourth quarter, Balchem’s strong growth trajectory continued. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line growth year over year in each of our three segments, driven by ongoing progress on our focused growth platforms and our company’s alignment with the favorable ‘better for you’ trends.”
Fourth Quarter 2025 Financial Highlights:
- Net sales of
$263.6 million , an increase of9.8% compared to the prior year quarter. - GAAP net earnings were
$39.2 million , an increase of16.8% from the prior year quarter. - Adjusted EBITDA was
$67.9 million , an increase of8.1% from the prior year quarter. - GAAP earnings per share of
$1.21 compared to$1.03 in the prior year quarter and adjusted earnings per share(a) of$1.31 compared to$1.13 in the prior year quarter. - Cash flows from operations were
$67.3 million , with free cash flow of$51.2 million . - Sales and earnings from operations growth in all three of our reporting segments.
Mr. Harris added, “For the full year 2025, Balchem delivered another very strong year, with record net sales, adjusted EBITDA, and free cash flow, allowing us to increase our dividend once again by a double digit percentage while further strengthening our balance sheet.”
Full Year 2025 Financial Highlights:
- Record full year net sales of
$1.037 billion , an increase of8.8% compared to the prior year. - Record GAAP net earnings were
$154.8 million , an increase of20.5% from the prior year. These net earnings resulted in record GAAP earnings per share of$4.75 compared to$3.93 in the prior year. - Record adjusted EBITDA was
$274.9 million , an increase of9.8% , from the prior year. - Record adjusted net earnings were
$167.9 million , an increase of17.4% from the prior year. These adjusted net earnings resulted in record adjusted earnings per share of$5.15 compared to$4.37 in the prior year. - Record cash flows from operations were
$216.6 million for 2025, with record free cash flow of$173.6 million .
Mr. Harris continued, “As we look ahead to 2026 and beyond, I continue to be excited about our future and believe we are well positioned to deliver ongoing above market growth for our shareholders.”
| Results for Period Ended December 31, 2025 (unaudited) (Dollars in thousands, except per share data) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Net sales | $ | 263,617 | $ | 240,004 | $ | 1,037,161 | $ | 953,684 | ||||
| Gross margin | 93,899 | 86,337 | 370,633 | 336,206 | ||||||||
| Operating expenses | 41,609 | 38,893 | 161,307 | 153,297 | ||||||||
| Earnings from operations | 52,290 | 47,444 | 209,326 | 182,909 | ||||||||
| Interest and other expenses | 2,255 | 2,960 | 10,296 | 16,456 | ||||||||
| Earnings before income tax expense | 50,035 | 44,484 | 199,030 | 166,453 | ||||||||
| Income tax expense | 10,810 | 10,901 | 44,185 | 37,978 | ||||||||
| Net earnings | $ | 39,225 | $ | 33,583 | $ | 154,845 | $ | 128,475 | ||||
| Diluted net earnings per common share | $ | 1.21 | $ | 1.03 | $ | 4.75 | $ | 3.93 | ||||
| Adjusted EBITDA(a) | $ | 67,893 | $ | 62,833 | $ | 274,854 | $ | 250,348 | ||||
| Adjusted net earnings(a) | $ | 42,338 | $ | 36,876 | $ | 167,898 | $ | 142,965 | ||||
| Adjusted diluted net earnings per common share(a) | $ | 1.31 | $ | 1.13 | $ | 5.15 | $ | 4.37 | ||||
| Shares used in the calculations of diluted and adjusted net earnings per common share | 32,320 | 32,548 | 32,604 | 32,718 | ||||||||
| (a) | See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures. |
Financial Results for the Fourth Quarter of 2025:
The Human Nutrition and Health segment generated fourth quarter sales of
The Animal Nutrition and Health segment generated quarterly sales of
The Specialty Products segment generated fourth quarter sales of
Consolidated quarterly gross margin of
Net interest expense was
For the quarter ended December 31, 2025, cash flows provided by operating activities were
Ted Harris, Chairman, President, and CEO of Balchem said, “2025 was another very strong year for Balchem and I would like to thank all of our over 1,300 employees for their contributions to these results and the progress we have made on our strategic growth initiatives.”
| (b) | Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents. |
| (c) | Leverage ratio is defined as net debt divided by the trailing twelve months adjusted EBITDA. |
Quarterly Conference Call
A quarterly conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter 2025 results. Ted Harris, Chairman, President and CEO and Martin Bengtsson, CFO will host the call. Institutional investors, analysts and other members of the financial community are invited to join the live call by dialing 800-715-9871 (toll free USA/Canada), +1-646-307-1963 (USA/International) or 647-932-3411 (Canada/Toronto), and referencing Conference ID 4400943, five minutes prior to the scheduled start time of the conference call. Investors and the public are invited to listen to the live webcast at https://events.q4inc.com/attendee/732063713. The conference call will be available for replay shortly after the conclusion of the call at https://events.q4inc.com/attendee/732063713 for one year.
Segment Information
Balchem Corporation reports three business segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition and Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition and Health segment manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged performance gases for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".
Forward-Looking Statements
This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "forecast," "outlook," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," or the negative thereof or variations thereon or similar expressions generally intended to identify forward-looking statements. Forward-looking statements may relate to such matters as projections of revenue, margins, expenses, tax provisions, earnings, cash flows, benefit obligations, dividends, share purchases or other financial items; any statements of the plans, strategies and objectives of management for future operations, including those relating to any statements concerning expected development, performance or market share relating to our products and services; any statements regarding future economic conditions or our performance; any statements regarding pending investigations, claims or disputes; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. These statements are based on the Company's currently available information and our reasonable assumptions, expectations and projections about future events. They are subject to future events, risks and uncertainties - many of which are beyond the Company’s control - as well as potentially inaccurate assumptions, that could cause actual results to differ materially from those in the forward-looking statements. Important factors and other risks that may affect the Company's business or that could cause actual results to differ materially are included in filings the Company makes with the U.S. Securities and Exchange Commission from time to time, including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, its Current Reports on Form 8-K, and in its other SEC filings. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Jacqueline Yarmolowicz, Balchem Corporation (Telephone: 845-326-5600)
Selected Financial Data (unaudited)
(Dollars in thousands)
Business Segment Net Sales:
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| Human Nutrition and Health | $ | 166,069 | $ | 147,303 | $ | 659,387 | $ | 600,258 | ||||
| Animal Nutrition and Health | 61,171 | 58,326 | 230,852 | 214,710 | ||||||||
| Specialty Products | 34,833 | 32,851 | 140,976 | 132,749 | ||||||||
| Other(d) | 1,544 | 1,524 | 5,946 | 5,967 | ||||||||
| Total | $ | 263,617 | $ | 240,004 | $ | 1,037,161 | $ | 953,684 | ||||
| (d) Other consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. | ||||||||||||
Business Segment Earnings Before Income Taxes:
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Human Nutrition and Health | $ | 36,759 | $ | 33,755 | $ | 153,906 | $ | 135,957 | ||||||||
| Animal Nutrition and Health | 6,224 | 5,731 | 18,687 | 14,013 | ||||||||||||
| Specialty Products | 10,513 | 9,963 | 42,901 | 39,906 | ||||||||||||
| Other and Unallocated(e) | (1,206 | ) | (2,005 | ) | (6,168 | ) | (6,967 | ) | ||||||||
| Interest and other expenses | (2,255 | ) | (2,960 | ) | (10,296 | ) | (16,456 | ) | ||||||||
| Total | $ | 50,035 | $ | 44,484 | $ | 199,030 | $ | 166,453 | ||||||||
| (e) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of transaction and integration costs of | ||||||||||||||||
| Selected Balance Sheet Items | ||||||
| (Dollars in thousands) | December 31, 2025 | December 31, 2024 | ||||
| Cash and cash equivalents | $ | 74,570 | $ | 49,515 | ||
| Accounts receivable, net | 143,596 | 119,662 | ||||
| Inventories | 131,449 | 130,802 | ||||
| Other current assets | 15,999 | 13,791 | ||||
| Total current assets | 365,614 | 313,770 | ||||
| Property, plant and equipment, net | 306,648 | 282,154 | ||||
| Goodwill | 816,375 | 780,030 | ||||
| Intangible assets with finite lives, net | 163,289 | 165,050 | ||||
| Right of use assets | 16,192 | 17,050 | ||||
| Other assets | 18,134 | 17,317 | ||||
| Total non-current assets | 1,320,638 | 1,261,601 | ||||
| Total assets | $ | 1,686,252 | $ | 1,575,371 | ||
| Current liabilities | $ | 176,384 | $ | 157,685 | ||
| Revolving loan | 164,000 | 190,000 | ||||
| Deferred income taxes | 54,143 | 43,722 | ||||
| Other long-term obligations | 34,312 | 34,051 | ||||
| Total liabilities | 428,839 | 425,458 | ||||
| Stockholders' equity | 1,257,413 | 1,149,913 | ||||
| Total liabilities and stockholders' equity | $ | 1,686,252 | $ | 1,575,371 | ||
| Balchem Corporation Condensed Consolidated Statements of Cash Flows (Dollars in thousands) (unaudited) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net earnings | $ | 154,845 | $ | 128,475 | ||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 45,690 | 47,973 | ||||||
| Stock compensation expense | 18,057 | 16,675 | ||||||
| Other adjustments | 5,427 | (5,007 | ) | |||||
| Changes in assets and liabilities, net of acquired balances | (7,463 | ) | (6,117 | ) | ||||
| Net cash provided by operating activities | 216,556 | 181,999 | ||||||
| Cash flows from investing activities: | ||||||||
| Capital expenditures and intangible assets acquired | (43,489 | ) | (35,661 | ) | ||||
| Cash paid for acquisitions, net of cash acquired | (323 | ) | (24,164 | ) | ||||
| Proceeds from sale of assets | 274 | 359 | ||||||
| Investment in affiliates | (353 | ) | (270 | ) | ||||
| Net cash used in investing activities | (43,891 | ) | (59,736 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from revolving loan | 88,000 | 26,000 | ||||||
| Principal payments on revolving debt | (114,000 | ) | (145,569 | ) | ||||
| Principal payments on finance lease | (194 | ) | (216 | ) | ||||
| Proceeds from stock options exercised | 9,307 | 17,228 | ||||||
| Dividends paid | (28,287 | ) | (25,576 | ) | ||||
| Repurchases of common stock | (107,636 | ) | (5,682 | ) | ||||
| Net cash used in financing activities | (152,810 | ) | (133,815 | ) | ||||
| Effect of exchange rate changes on cash | 5,200 | (3,380 | ) | |||||
| Increase (decrease) in cash and cash equivalents | 25,055 | (14,932 | ) | |||||
| Cash and cash equivalents, beginning of period | 49,515 | 64,447 | ||||||
| Cash and cash equivalents, end of period | $ | 74,570 | $ | 49,515 | ||||
Non-GAAP Financial Information
In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, free cash flow, net debt, and leverage ratio. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain equity compensation, nonqualified deferred compensation plan expense (income), and certain one-time or unusual transactions. Detailed non-GAAP adjustments are described in the reconciliation tables below and also explained in the related footnotes. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Investors should not consider non-GAAP measures as alternatives to the related GAAP measures.
Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
Table 1
(unaudited)
| Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Reconciliation of adjusted gross margin | ||||||||||||||||
| GAAP gross margin | $ | 93,899 | $ | 86,337 | $ | 370,633 | $ | 336,206 | ||||||||
| Amortization of intangible assets and finance lease(1) | 733 | 702 | 2,889 | 2,806 | ||||||||||||
| Adjusted gross margin | $ | 94,632 | $ | 87,039 | $ | 373,522 | $ | 339,012 | ||||||||
| Reconciliation of adjusted earnings from operations | ||||||||||||||||
| GAAP earnings from operations | $ | 52,290 | $ | 47,444 | $ | 209,326 | $ | 182,909 | ||||||||
| Amortization of intangible assets and finance lease(1) | 4,384 | 3,917 | 17,203 | 19,476 | ||||||||||||
| Transaction and integration costs(2) | 15 | 689 | 1,242 | 1,393 | ||||||||||||
| Restructuring costs(3) | — | — | (192 | ) | 521 | |||||||||||
| Impairment charge(4) | — | — | — | 255 | ||||||||||||
| Nonqualified deferred compensation plan expense (income)(5) | 180 | (14 | ) | 1,019 | 908 | |||||||||||
| Adjusted earnings from operations | $ | 56,869 | $ | 52,036 | $ | 228,598 | $ | 205,462 | ||||||||
| Reconciliation of adjusted net earnings | ||||||||||||||||
| GAAP net earnings | $ | 39,225 | $ | 33,583 | $ | 154,845 | $ | 128,475 | ||||||||
| Amortization of intangible assets and finance lease(1) | 4,455 | 3,988 | 17,490 | 19,763 | ||||||||||||
| Transaction and integration costs(2) | 15 | 689 | 1,242 | 1,393 | ||||||||||||
| Restructuring costs(3) | — | — | (192 | ) | 521 | |||||||||||
| Impairment charge(4) | — | — | — | 255 | ||||||||||||
| Income tax adjustment(6) | (1,357 | ) | (1,384 | ) | (5,487 | ) | (7,442 | ) | ||||||||
| Adjusted net earnings | $ | 42,338 | $ | 36,876 | $ | 167,898 | $ | 142,965 | ||||||||
| Adjusted net earnings per common share - diluted | $ | 1.31 | $ | 1.13 | $ | 5.15 | $ | 4.37 | ||||||||
Table 2
(unaudited)
| Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands) | ||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||
| Net earnings - as reported | $ | 39,225 | $ | 33,583 | $ | 154,845 | $ | 128,475 | ||||||
| Add back: | ||||||||||||||
| Provision for income taxes | 10,810 | 10,901 | 44,185 | 37,978 | ||||||||||
| Interest and other expenses | 2,255 | 2,960 | 10,296 | 16,456 | ||||||||||
| Depreciation and amortization | 11,649 | 10,825 | 45,402 | 47,686 | ||||||||||
| EBITDA | 63,939 | 58,269 | 254,728 | 230,595 | ||||||||||
| Add back: | ||||||||||||||
| Non-cash compensation expense related to equity awards | 3,759 | 3,889 | 18,057 | 16,676 | ||||||||||
| Transaction and integration costs(2) | 15 | 689 | 1,242 | 1,393 | ||||||||||
| Restructuring costs(3) | — | — | (192 | ) | 521 | |||||||||
| Impairment charge(4) | — | — | — | 255 | ||||||||||
| Nonqualified deferred compensation plan expense (income)(5) | 180 | (14 | ) | 1,019 | 908 | |||||||||
| Adjusted EBITDA | $ | 67,893 | $ | 62,833 | $ | 274,854 | $ | 250,348 | ||||||
Table 3
(unaudited)
| Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands) | ||||||||||||
| Three Months Ended December 31, | ||||||||||||
| 2025 | Effective Tax Rate | 2024 | Effective Tax Rate | |||||||||
| GAAP Income Tax Expense | $ | 10,810 | 21.6 | % | $ | 10,901 | 24.5 | % | ||||
| Impact of ASU 2016-09(7) | 360 | 202 | ||||||||||
| Adjusted Income Tax Expense | $ | 11,170 | 22.3 | % | $ | 11,103 | 25.0 | % | ||||
| Year Ended December 31, | ||||||||||||
| 2025 | Effective Tax Rate | 2024 | Effective Tax Rate | |||||||||
| GAAP Income Tax Expense | $ | 44,185 | 22.2 | % | $ | 37,978 | 22.8 | % | ||||
| Impact of ASU 2016-09(7) | 1,254 | 2,154 | ||||||||||
| Adjusted Income Tax Expense | $ | 45,439 | 22.8 | % | $ | 40,132 | 24.1 | % | ||||
Table 4
(unaudited)
| Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Dollars in thousands) | ||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net cash provided by operating activities | $ | 67,275 | $ | 52,317 | $ | 216,556 | $ | 181,999 | ||||||||
| Capital expenditures and proceeds from the sale of assets | (16,053 | ) | (12,549 | ) | (42,919 | ) | (34,789 | ) | ||||||||
| Free cash flow | $ | 51,222 | $ | 39,768 | $ | 173,637 | $ | 147,210 | ||||||||
| (1) Amortization of intangible assets and finance lease: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, other intangibles acquired primarily in connection with business combinations, and finance leases. We record expense relating to the amortization of these intangibles and finance leases in our GAAP financial statements. Amortization expenses for our intangible assets and finance leases are inconsistent in amount and are significantly impacted by the timing and valuation of acquisitions. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance. |
| (2) Transaction and integration costs: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (3) Restructuring costs: Restructuring costs related to a reorganization of the business are recorded in our GAAP financial statements. Management excludes these items for the purposes of calculating adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with transactions that are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
| (4) Impairment charge: An asset impairment charge in 2024 was related to the write off of an equity method investment. The impairment charge is included in our GAAP financial statements. Management excludes this item for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding this item from our non-GAAP financial measures is useful to investors because it is inconsistent in amount of frequency causing comparison of current and historical financial results to be difficult. |
| (5) Nonqualified deferred compensation plan expense (income): Gains and losses on rabbi trust assets related to our nonqualified deferred compensation plan are recorded in other expense (income) while the offsetting increases or decreases to the deferred compensation liability are recorded within earnings from operations. The increases and decreases in the deferred compensation liability are driven by market volatility and are not a true reflection of company performance. We believe excluding these amounts from our non-GAAP financial measures is useful to investors because these items are inconsistent in amount based on market conditions causing comparison of current and historical financial results to be difficult. |
| (6) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate. |
| (7) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and twelve months ended December 31, 2025 and 2024, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities. Management excludes this item for the purpose of calculating adjusted Income Tax Expense. We believe that excluding the item in our non-GAAP financial measures is useful to investors because it is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult. |
